Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novartis

First malaria drug for babies is approved in ‘major public health milestone’

WHO prequalification of Coartem Baby means newborns can be safely treated rather than using medication for older children

The Guardian - UK

Carrie Ann Inaba shares health update after suffering medical emergency on flight

The ‘DWTS’ judge was on a flight to New York City for a campaign for her pharmaceutical company, Novartis

The Independent UK

Scotland becomes first part of UK to screen babies for rare muscle disease

All parents will now be offered spinal muscular atrophy screening for their newborns.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Exclusive: Oro Labs, which is using AI to streamline companies' procurement processes, raises $100 million in fresh venture capital funding

Goldman Sachs Equity Growth and Brighton Park Capital lead the funding round for the company, which says it can reduce procurement process times from weeks to days or hours

Fortune

Novartis settles with Henrietta Lacks' estate over use of her 'stolen' cells to advance medicine

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine

The Independent UK

Tony Gonzalez Shares the One Question Travis Kelce Should Ask Himself Before Retiring

Gonzalez spoke to Sports Illustrated in an exclusive interview about Kelce’s NFL future.

Sports Illustrated

Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?

Novartis (NVS) is trading at new all-time highs on Monday. Shares are up nearly 50% over the past 52 weeks. NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent days from its CEO’s comments that the company will have essentially limited tariff exposure by mid-2026....

Barchart

Read news from The Economist, FT, and more,
with one subscription

Inside Big Pharma and VC’s big bet on AI: You wouldn’t ‘want to fly an airplane designed by hand, but all of our drugs are designed like that’

Silicon Valley and Wall Street are pouring billions into AI drug discovery in a high-stakes bet to “solve” disease.

Fortune

Despite Trump pressure, Big Pharma is raising hundreds of drug prices

Costs of at least 350 branded medications, including vaccines against Covid-19, shingles and cancer treatment Ibrance, will reportedly be hiked

The Independent UK

Four Convicted in $600K Insider Trading Scheme — Don't Risk Your Savings

A former Chinook Therapeutics executive and his associates were convicted of insider trading, profiting over $600,000 from a major merger with Novartis.

International Business Times UK

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Novartis AG (NYSE:NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.

Benzinga

New malaria treatment could fight growing threat of drug resistance

Drugmaker Novartis said it will move quickly to ask regulators to approve the new medicine.

Euronews

2 new malaria treatments announced as drug resistance grows

Researchers are reporting two promising approaches to counteract malaria's growing drug resistance

The Independent UK

Scientists unveil new anti-malaria drug with ‘very high cure rate’

Treatment could be ‘the biggest advance in malaria treatment for decades,’ expert says

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Scientists create new anti-malaria drug with ‘very high cure rate’

Experts said they were "very excited" by the findings

Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

Benzinga

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.

Benzinga

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain

Novartis AG (NYSE:NVS) on Wednesday shared topline data from the Phase 3 REPLENISH trial of Cosentyx in patients with polymyalgia rheumatica.

Benzinga

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

On Friday, Novartis AG (NYSE:NVS) shared results from the five-year analysis of the Phase 3 NATALEE trial of Kisqali (ribociclib).

Benzinga

Novartis Strengthens Kidney Disease Pipeline With Promising Data

Novartis A/S (NYSE:NVS) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta (iptacopan) in adults with IgA nephropathy (IgAN).

Fortune

Logitech CEO Hanneke Faber says she would consider adding an AI agent to her board of directors

Also: All the news and watercooler chat from Fortune.

Fortune

CEO says she’d welcome an AI-bot board member: ‘If you don’t have an AI agent in every meeting, you’re missing out’

Hanneke Faber speaks about the value of AI in decision-making at the Fortune Most Powerful Women Summit.

Barchart

Should You Buy Novartis Stock Before October 28?

Novartis is gaining traction this year, but can the trend continue?

Fortune

How high-cost Switzerland stayed a manufacturing powerhouse in the offshore era

What is the lesson of Swiss Fortune 500 companies—such as dsm-firmenich—for the rest of Europe, and the world?

1 2 3 4 5

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.